乙胺吡嗪利福异烟片(Ⅱ)治疗肺结核致不良反应/事件106例分析  

Analysis of 106 ADR/ADE Induced by Ethambutol Hydrochloride,Pyrazinamide,Rifampicin and Isoniazid Tablets(Ⅱ)in the Treatment of Pulmonary Tuberculosis

作　　者：肖招英 钱华飞[1] 

机构地区：[1]嵊州市人民医院感染科,浙江嵊州312400

出　　处：《中国药房》2014年第24期2286-2288,共3页China Pharmacy

摘　　要：目的:探讨肺结核患者应用乙胺吡嗪利福异烟片(Ⅱ)致不良反应/事件(ADR/ADE)的一般规律及特点,为临床合理用药及安全性评价提供参考。方法:采用回顾性研究方法,对2011年1月-2013年10月间接受乙胺吡嗪利福异烟片(Ⅱ)治疗的386例肺结核患者中发生ADR/ADE的相关情况进行统计和分析。结果:386例患者出现ADR/ADE共106例,发生率为27.46%。ADR/ADE发生时间最多见于用药2周内(92.45);其中,胃肠系统损害构成比为38.71%,皮肤及其附件损害构成比为29.57%,肝胆系统损害构成比为19.35%,居前3位;经停药、调整用法用量或对症治疗后105例(99.06%)好转或痊愈。结论:临床应掌握乙胺吡嗪利福异烟片(Ⅱ)所致ADR/ADE的特点,加强监测,并及时发现和正确处理,从而可提高肺结核患者的用药依从性和治愈率。OBJECTIVE： To investigate the characteristics and general pattern of ADR/ADE induced by Ethambutol hydrochloride, pyrazinamide, rifampicin and isoniazid （EHPRI） tablets （ Ⅱ） in patients with pulmonary tuberculosis, and to provide reference for rational drug use and safety evaluation. METHODS： By retrospective study, ADR/ADE of 386 patients with pulmonary tuberculosis receiving EHPRI tablet （ Ⅱ ） during Jan. 2011- Oct. 2013 were analyzed statistically. RESULTS： There were 106 cases of ADR/ADE in 386 patients with the incidence of 27.46%. ADR mainly occurred within first 2 week after medication （92.45%）; top 3 clinical manifestations were gastrointestinal reactions （38.71% ）, lesion of skin and its appendants （29.57 % ）, and hepatobiliary system damage （19.35%）. 105 cases were improved or cured after drug withdrawal, adjusting usage and dosage or symptomatic treatment （99.06%）. CONCLUSIONS： Great importance should be attached to the characteristics of EHPRI tablet （ Ⅱ ） and ADR monitoring, and find and dispose ADR timely so as to improve the medication compliance and cure rate of patients with pulmonary tuberculosis.

关 键 词：乙胺吡嗪利福异烟片(Ⅱ) 不良反应 事件 分析 合理用药 

分 类 号：R969.3[医药卫生—药理学]